29 August 2018

ProteoMediX raised CHF 5.2 m in Series B Financing Round

ProteoMediX AG, a diagnostic company developing blood-based tests for the accurate diagnosis and prognosis of prostate cancer, successfully closed an equity financing round. The company raised CHF 5.2 mio. from existing investors.
 
VISCHER advised on all Swiss legal issues related to the transaction. The VISCHER team includes Mattias Staehelin (Partner, Corporate/M&A) and Moritz Jäggy (Managing Associate, Corporate/M&A).

Share article on:

Service(s) included:

Get in touch with our authors and benefit from their expertise:

partner-Matthias-0

Matthias Staehelin

matthias.staehelin@vischer.com

+41 58 211 33 53

partner-Moritz-1

Moritz Jäggy

moritz.jaeggy@vischer.com

+41 58 211 32 33

Our
newsletter